The infection of the bone marrow system caused by methicillin-resistant Staphylococcus aureus (MRSA) leads to a variety of common diseases which usually occur in children under the age of 12. Vancomycin (VCM) is the first-line therapy for MRSA-caused serious infections such as bacteremia, infective endocarditis, osteomyelitis, meningitis, pneumonia, and severe skin and soft-tissue infection (e.g. necrotizing fasciitis) with a recommended dosage of 15–20 μg/mL. In this study, we first report a case of a child with MRSA-caused osteomyelitis who was successfully cured by VCM at a concentration of 4.86 μg/mL. VCM’s clinical daily dose of more than 4 g was of concern in light of recent evidence suggesting the increased risks of nephrotoxicity and red man syndrome when C_min ⩾15 μg/mL and doses ⩾10 mg/kg in children. As far as we know, this is the first report on the lower dose of VCM in children with MRSA osteomyelitis.

耐甲氧西林金黄色葡萄球菌（MRSA）引起的骨髓系统感染导致多种常见疾病，通常发生在12岁以下的儿童中。万古霉素（VCM）是MRSA引起的重症患者的一线治疗建议的剂量为15–20μg/ mL，例如菌血症，感染性心内膜炎，骨髓炎，脑膜炎，肺炎以及严重的皮肤和软组织感染（如坏死性筋膜炎）。在这项研究中，我们首先报道了一名儿童，由MRSA引起的骨髓炎，其通过VCM以4.86μg/ mL的浓度成功治愈。鉴于最近的证据表明，当C_分钟时肾毒性和红人综合症的风险增加，VCM的临床日剂量超过4 g引起关注儿童children15μg/ mL，剂量⩾10mg / kg。据我们所知，这是关于MRSA骨髓炎患儿较低VCM剂量的首次报道。